. Overview We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-12 | 2025-09-30 | 0001171843-25-007914 | EDGAR | 73K words |
| 2024-12-13 | 2024-09-30 | 0001171843-24-006946 | EDGAR | — |
| 2023-12-15 | 2023-09-30 | 0001654954-23-015632 | EDGAR | — |
| 2022-12-16 | 2022-09-30 | 0001654954-22-016633 | EDGAR | — |
| 2021-12-28 | 2021-09-30 | 0001654954-21-013551 | EDGAR | — |
| 2020-12-07 | 2020-09-30 | 0001654954-20-013236 | EDGAR | — |
| 2018-11-30 | 2018-09-30 | 0001144204-18-062614 | EDGAR | — |
| 2017-12-01 | 2017-09-30 | 0001144204-17-061791 | EDGAR | — |
| 2016-12-14 | 2016-09-30 | 0001144204-16-139528 | EDGAR | — |
| 2015-12-14 | 2015-09-30 | 0001144204-15-070753 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-13 | 2025-12-31 | 0001171843-26-000812 | EDGAR | 17K words |
| 2025-08-08 | 2025-06-30 | 0001171843-25-005236 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001171843-25-003189 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001171843-25-000866 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001171843-24-004651 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001654954-24-005971 | EDGAR | — |
| 2024-02-09 | 2023-12-31 | 0001654954-24-001540 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001654954-23-010380 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001654954-23-006231 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001654954-23-001577 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001654954-22-011208 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001654954-22-006659 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001171843-26-001046 | EDGAR | 2K words |
| 2026-02-13 | 0001171843-26-000810 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007918 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007913 | EDGAR | — |
| 2025-10-28 | 0001171843-25-006690 | EDGAR | — |
| 2025-09-30 | 0001171843-25-006188 | EDGAR | — |
| 2025-09-09 | 0001171843-25-005800 | EDGAR | — |
| 2025-08-08 | 0001171843-25-005235 | EDGAR | — |
| 2025-05-28 | 0001171843-25-003495 | EDGAR | — |
| 2025-05-14 | 0001171843-25-003183 | EDGAR | — |
315 total filings indexed. 283 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001540159 |
| Ticker | EDSA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Website | https://www.edesabiotech.com |
| Listed | 2010-06-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EDSA (~200 tokens, structured JSON with cryptographic provenance)